Tanvi Dinesh Premchandani

Dr. Tanvi Dinesh Premchandani

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
MUMilind Janrao Umekar
Milind Janrao Umekar
MQMohammad Qutub
Mohammad Qutub
PSPriyanka Singanwad
Priyanka Singanwad
Engineered exosomes have emerged as transformative drug carriers, uniquely equipped to overcome biological barriers in central nervous system (CNS) disorders and cancer therapy. These natural extracellular vesicles, derived from cell membranes, offer inherent biocompatibility, low immunogenicity, and the ability to traverse physiological obstacles such as the blood–brain barrier (BBB) and dense tumor stroma. Recent advances in exosome engineering—including surface modification (e.g., ligand conjugation for receptor-mediated targeting) and cargo loading (siRNA, CRISPR-Cas systems, and chemotherapeutics)—have enhanced their precision and therapeutic utility. For CNS delivery, exosomes functionalized with brain-homing peptides (e.g., RVG or TfR ligands) have enabled the efficient transport of neuroprotective agents or gene-editing tools to treat Alzheimer’s disease or glioblastoma. In oncology, engineered exosomes loaded with tumor-suppressive miRNAs or immune checkpoint inhibitors exploit tumor microenvironment (TME) features, such as acidity or enzyme overexpression, for spatially controlled drug release. Furthermore, hybrid exosome–liposome systems and exosome–biomaterial composites are being explored to improve payload capacity and stability. Despite progress, challenges persist in scalable production, batch consistency, and regulatory standardization. This review critically evaluates engineering strategies, preclinical success, and translational hurdles while proposing innovations such as AI-driven exosome design and patient-derived exosome platforms for personalized therapy. By bridging nanotechnology and biomedicine, engineered exosomes can represent a paradigm shift in targeted drug delivery, offering safer and more effective solutions for historically intractable diseases.

5 April 2025 in Brain Disorders
Verified
Journal Article
Open access
MUMilind Umekar
Milind Umekar
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
ATAmol Tatode
Amol Tatode
MQMohammad Qutub
Mohammad Qutub
NRNeha Raut
Neha Raut
UHUjban Md. Hussain
Ujban Md. Hussain

4 December 2025 in Bacteria
Verified
Journal Article
Open access
PDF file
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
MUMilind Janrao Umekar
Milind Janrao Umekar
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
RKRahmuddin khan
Rahmuddin khan
MQMohammad Qutub
Mohammad Qutub
Extracellular vesicles, encompassing eukaryotic exosomes and bacterial outer membrane vesicles (OMVs), play multifaceted roles in mediating host–pathogen interactions. These nanoscale structures act as critical mediators of intercellular communication, transporting diverse bioactive cargo such as miRNAs, cytokines, proteins, and bacterial components. Exosomes contribute to host immunity by delivering antimicrobial agents and modulating inflammatory responses, but they can also be hijacked by pathogens to suppress defenses and promote persistent infection. OMVs, on the other hand, enable bacteria to disseminate virulence factors, deliver toxins directly into host cells, and modulate immune signaling. For example, exosomes from infected macrophages can stimulate dendritic cell activation and T-cell priming, whereas bacterial OMVs have been shown to suppress host immunity or trigger excessive inflammation depending on their molecular cargo. Importantly, OMVs facilitate horizontal gene transfer and nutrient exchange within microbial communities, thereby influencing microbiome composition and adaptation. Together, these complex dynamics position both exosomes and OMVs as central players in immunity and pathogenesis. This review synthesizes recent insights into how host- and pathogen-derived vesicles modulate infection biology and immune responses, while also exploring their potential as diagnostic biomarkers and therapeutic carriers, and discussing current limitations in their clinical translation.

3 April 2025 in Bacteria
Verified
Journal Article
Open access
PDF file
MQMohammad Qutub
Mohammad Qutub
ATAmol A. Tatode
Amol A. Tatode
UHUjban Hussain
Ujban Hussain
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
JTJayshree Taksande
Jayshree Taksande
DTDeepak Arjun Thakre
Deepak Arjun Thakre
Clostridioides difficile Infection (CDI) continues to be a major cause of antibiotic-associated diarrhea and pseudomembranous colitis, fueled in large measure by virulence factors TcdA and TcdB. These giant glucosyltransferase toxins interfere with host cytoskeletal integrity and inflammatory signaling by inhibiting Rho GTPase; however, the detailed structural dynamics, receptor selectivity, and subcellular trafficking mechanisms remain in part unspecified. This review integrates recent insights from cryo-electron microscopy (cryo-EM) and X-ray crystallography to describe the quaternary architecture of TcdA/B, emphasizing conformational changes key to pore formation and endosomal escape. We also examine the genomic heterogeneity of hypervirulent C. difficile strains (e.g., ribotype 027), correlating toxin gene polymorphisms (e.g., tcdC mutations) with increased toxin production and virulence. Mechanistic explanations of toxin-driven inflammasome activation and epithelial barrier dysfunction are situated within host immune evasion mechanisms, including microbiota-derived bile acid regulation of toxin stability. Subsequent innovative therapeutic strategies, encompassing the utilization of engineered neutralizing antibodies that specifically target the autoprocessing domain alongside structure-guided small-molecule inhibitors, are subjected to a rigorous evaluation. By integrating structural biology, systems-level omics, and clinical epidemiology, this review establishes a comprehensive framework for understanding C. difficile toxin pathogenesis and guiding next-generation precision antimicrobials.

7 April 2026 in Human Immunology
Verified
Journal Article
Closed access
MQMohammad Qutub
Mohammad Qutub
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
SBSakshi Bhagat
Sakshi Bhagat
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
RKRahmuddin Khan
Rahmuddin Khan

27 November 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
MQMohammad Qutub
Mohammad Qutub
SSSohail S. Sheikh
Sohail S. Sheikh
ATAmol A. Tatode
Amol A. Tatode
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
SNSakshi Nalkande
Sakshi Nalkande
RKRahmuddin Khan
Rahmuddin Khan